MedTrace Logo

Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections

NCT06126263 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2023-11-13

No results posted yet for this study

Summary

This study aims to emulate a hypothetical target pragmatic multi-center, non-blinded trial of adult inpatients in the PINC AITM dataset with B-lactam treated culture confirmed monomicrobial invasive Group A streptococcus (GAS) between the years 2015-2021

Conditions

  • Streptococcal Sepsis
  • Invasive Group A Beta-Haemolytic Streptococcal Disease
  • Necrotizing Soft Tissue Infection
  • Infection, Bloodstream
  • Infection, Bacterial
  • Streptococcal Toxic Shock Syndrome

Interventions

DRUG

Linezolid

Adjunctive antitoxin therapy

DRUG

Clindamycin

Adjunctive antitoxin therapy

Sponsors & Collaborators

  • Emory University

    collaborator OTHER

  • National Institutes of Health Clinical Center (CC)

    lead NIH

Principal Investigators

  • Ahmed Babiker · Emory University

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2024-04-30
Completion
2024-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06126263 on ClinicalTrials.gov